Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 1;15:100381. doi: 10.1016/j.jvacx.2023.100381

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 3 — Clinical course of long COVID symptoms after vaccination (a) Time course of long COVID in vaccinated patients. Fifteen participants reported resolution of some COVID-19 symptoms after vaccination. Eleven reported complete resolution of all symptoms: one after the first vaccination, eight after the second vaccination, and two after the third vaccination. (b) Detailed trends in the improvement of long COVID symptoms during clinical course Participants reported improvements in several types of long-term COVID symptoms after vaccination; dyspnea and alopecia improved most frequently. Symptoms, such as sleep disorders, myalgia, hypersensitivity, eruption, and sputum, persisted until the end of the follow-up period.

Fig. 3 — Clinical course of long COVID symptoms after vaccination (a) Time course of long COVID in vaccinated patients. Fifteen participants reported resolution of some COVID-19 symptoms after vaccination. Eleven reported complete resolution of all symptoms: one after the first vaccination, eight after the second vaccination, and two after the third vaccination. (b) Detailed trends in the improvement of long COVID symptoms during clinical course Participants reported improvements in several types of long-term COVID symptoms after vaccination; dyspnea and alopecia improved most frequently. Symptoms, such as sleep disorders, myalgia, hypersensitivity, eruption, and sputum, persisted until the end of the follow-up period.